These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11026015)

  • 21. [Mechanism of acquired antiestrogen resistance and its management in breast cancer].
    Iino Y; Maemura M; Morishita Y
    Nihon Rinsho; 1997 May; 55(5):1149-54. PubMed ID: 9155167
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pure oestrogen antagonists for the treatment of advanced breast cancer.
    Howell A
    Endocr Relat Cancer; 2006 Sep; 13(3):689-706. PubMed ID: 16954425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription.
    Nawaz Z; Stancel GM; Hyder SM
    Cancer Res; 1999 Jan; 59(2):372-6. PubMed ID: 9927049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Breakthrough in ER+ breast cancer. Specific gene's shutdown is detectable in blood; indicates cancer cell vulnerability, thus enabling earlier treatment.
    Duke Med Health News; 2013 Oct; 19(10):7. PubMed ID: 24288815
    [No Abstract]   [Full Text] [Related]  

  • 25. New treatment for advanced breast cancer.
    FDA Consum; 2002; 36(4):6. PubMed ID: 12184311
    [No Abstract]   [Full Text] [Related]  

  • 26. [A case of advanced breast cancer successfully treated with combined tamoxifen and epitiostanol].
    Konishi Y; Morimoto T; Komaki K; Yamakawa T; Mituyama N; Tanaka T; Oomine Y; Monden Y
    Gan To Kagaku Ryoho; 1988 Jul; 15(7):2163-7. PubMed ID: 3395140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fulvestrant (AstraZeneca).
    Johnston SR
    Curr Opin Investig Drugs; 2002 Feb; 3(2):305-12. PubMed ID: 12020064
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case studies of fulvestrant ("Faslodex") in postmenopausal women with advanced breast cancer.
    Abram P; Maass N; Rea D; Simon SD; Steger GG
    Cancer Treat Rev; 2005; 31 Suppl 2():S17-25. PubMed ID: 16199128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer.
    Howell A; DeFriend D; Robertson J; Blamey R; Walton P
    Lancet; 1995 Jan; 345(8941):29-30. PubMed ID: 7799704
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen.
    Lipton A; Ali SM; Leitzel K; Demers L; Harvey HA; Chaudri-Ross HA; Brady C; Wyld P; Carney W
    J Clin Oncol; 2003 May; 21(10):1967-72. PubMed ID: 12743150
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospects for combining hormonal and nonhormonal growth factor inhibition.
    Wakeling AE; Nicholson RI; Gee JM
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4350s-4355s; discussion 4411s-4412s. PubMed ID: 11916224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A potent specific pure antiestrogen with clinical potential.
    Wakeling AE; Dukes M; Bowler J
    Cancer Res; 1991 Aug; 51(15):3867-73. PubMed ID: 1855205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carcinoembryonic antigen cell adhesion molecule 6 predicts breast cancer recurrence following adjuvant tamoxifen.
    Maraqa L; Cummings M; Peter MB; Shaaban AM; Horgan K; Hanby AM; Speirs V
    Clin Cancer Res; 2008 Jan; 14(2):405-11. PubMed ID: 18223215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular aspects of different mechanisms of tamoxifen resistance].
    Bachmann-Moisson N; Barberi-Heyob M; Merlin JL
    Bull Cancer; 1997 Jan; 84(1):69-75. PubMed ID: 9180863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fulvestrant in the treatment of postmenopausal women with advanced breast cancer.
    Gradishar W
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):445-53. PubMed ID: 16001952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hormonal treatment of advanced breast cancer.
    Tellez C; Jordan VC
    Surg Oncol Clin N Am; 1995 Oct; 4(4):751-77. PubMed ID: 8535909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of fulvestrant in the management of postmenopausal breast cancer.
    Krell J; Januszewski A; Yan K; Palmieri C
    Expert Rev Anticancer Ther; 2011 Nov; 11(11):1641-52. PubMed ID: 22050013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulatory mechanisms in breast cancer. Steroidal pure antiestrogens.
    Wakeling AE
    Cancer Treat Res; 1991; 53():239-57. PubMed ID: 1672080
    [No Abstract]   [Full Text] [Related]  

  • 39. Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects.
    Nicholson RI; Walker KJ; Bouzubar N; Wills RJ; Gee JM; Rushmere NK; Davies P
    Ann N Y Acad Sci; 1990; 595():316-27. PubMed ID: 2142873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic potential of pure antioestrogens in the treatment of breast cancer.
    Wakeling AE
    J Steroid Biochem Mol Biol; 1990 Dec; 37(6):771-5. PubMed ID: 2285589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.